TY - JOUR T1 - Selection of eligible participants for screening for lung cancer using primary care data JF - Thorax JO - Thorax DO - 10.1136/thoraxjnl-2021-217142 SP - thoraxjnl-2021-217142 AU - Emma L O'Dowd AU - Kevin ten Haaf AU - Jaspreet Kaur AU - Stephen W Duffy AU - William Hamilton AU - Richard B Hubbard AU - John K Field AU - Matthew EJ Callister AU - Sam M Janes AU - Harry J de Koning AU - Janette Rawlinson AU - David R Baldwin Y1 - 2021/10/29 UR - http://thorax.bmj.com/content/early/2021/10/28/thoraxjnl-2021-217142.abstract N2 - Lung cancer screening is effective if offered to people at increased risk of the disease. Currently, direct contact with potential participants is required for evaluating risk. A way to reduce the number of ineligible people contacted might be to apply risk-prediction models directly to digital primary care data, but model performance in this setting is unknown.Method The Clinical Practice Research Datalink, a computerised, longitudinal primary care database, was used to evaluate the Liverpool Lung Project V.2 (LLPv2) and Prostate Lung Colorectal and Ovarian (modified 2012) (PLCOm2012) models. Lung cancer occurrence over 5–6 years was measured in ever-smokers aged 50–80 years and compared with 5-year (LLPv2) and 6-year (PLCOm2012) predicted risk.Results Over 5 and 6 years, 7123 and 7876 lung cancers occurred, respectively, from a cohort of 842 109 ever-smokers. After recalibration, LLPV2 produced a c-statistic of 0.700 (0.694–0.710), but mean predicted risk was over-estimated (predicted: 4.61%, actual: 0.9%). PLCOm2012 showed similar performance (c-statistic: 0.679 (0.673–0.685), predicted risk: 3.76%. Applying risk-thresholds of 1% (LLPv2) and 0.15% (PLCOm2012), would avoid contacting 42.7% and 27.4% of ever-smokers who did not develop lung cancer for screening eligibility assessment, at the cost of missing 15.6% and 11.4% of lung cancers.Conclusion Risk-prediction models showed only moderate discrimination when applied to routinely collected primary care data, which may be explained by quality and completeness of data. However, they may substantially reduce the number of people for initial evaluation of screening eligibility, at the cost of missing some lung cancers. Further work is needed to establish whether newer models have improved performance in primary care data.Data may be obtained from a third party and are not publicly available. Data available through CPRD and NCRAS. ER -